Clinical Trial Update: SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating SX-682 in combination with carfilzomib, daratumumab-hyaluronidase, and dexamethasone for relapsed or refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))
• Decadron (Dexamethasone)
• Kyprolis (carfilzomib)
• SX-682

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING